NFKB2 and sclerosing cholangitis: NFKB2's targets are enriched in the phenotype “chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)” (Supplemental Fig. S18B).